Cadrenal Therapeutics, Inc. (CVKD) - Q1 2026 Filing Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on immune and thrombotic conditions. The reporting period covers the three months ended March 31, 2026. The Company's lead program, CAD-1005 (a 12-LOX inhibitor for heparin-induced thrombocytopenia), has received FDA Orphan Drug and Fast Track designations. The Company also holds assets for tecarfarin and frunexian. As of March 31, 2026, the Company had 2,506,817 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,496,540) | $(3,845,380) |
| Loss Per Share (Basic/Diluted) | $(1.04) | $(2.09) |
| Total Operating Expenses | $2,514,378 | $3,927,976 |
| Cash Used in Operating Activities | $(3,002,217) | $(4,648,755) |
| Cash and Cash Equivalents (End of Period) | $2,308,137 | $7,336,072 |
| Stockholders' Equity | $1,797,115 | $6,113,096 |
| Accumulated Deficit | $(41,456,685) | $(29,568,163) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 36% ($1.4 million) compared to Q1 2025. General and administrative expenses fell 23%, and research and development expenses fell 54%.
- Cash Position: Cash and cash equivalents declined by approximately $1.7 million during the quarter, primarily due to operating losses and increased prepaid expenses, partially offset by financing activities.
- Financing Activity: The Company raised net proceeds of approximately $1.3 million through its At-The-Market (ATM) facility, selling 168,690 shares at a weighted average price of $8.10.
- Asset Acquisitions: In late 2025, the Company acquired assets related to frunexian (from eXIthera) and CAD-1005 (from Veralox). These were accounted for as asset acquisitions with costs expensed as R&D due to lack of alternative future use at acquisition.
Outlook, Risks, and Subsequent Events
- Going Concern Uncertainty: The filing states that substantial doubt exists regarding the Company's ability to continue as a going concern for at least one year. Management projects that existing cash resources will not be sufficient to fund operations for the next 12 months without additional financing.
- Subsequent Event (Warrant Inducement): On April 1, 2026, the Company consummated a warrant inducement transaction. An investor exercised warrants to purchase 571,430 shares at a reduced price of $4.50, generating gross proceeds of approximately $2.5 million. The Company issued new warrants to the investor as consideration.
- Nasdaq Compliance: As of March 31, 2026, Stockholders' Equity ($1.8 million) was below the Nasdaq minimum requirement of $2.5 million. Management believes the April 1, 2026 warrant exercise proceeds restored compliance, though a deficiency letter from Nasdaq remains a risk.
- Future Funding: The Company plans to seek additional capital through strategic partnerships, equity offerings, or debt financings to fund its planned Phase 3 clinical trial for CAD-1005, with an anticipated NDA submission in 2029.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway following the $2.5 million warrant inducement proceeds received in April 2026.
- Nasdaq Status: Confirm whether Nasdaq has formally accepted the Company's compliance with the Stockholders' Equity requirement following the subsequent event.
- Dilution Impact: Assess the dilutive effect of the new Series B-1 and B-2 warrants issued in the April 2026 transaction (1.14 million new warrants issued).
- Contingent Liabilities: Review the potential future milestone payments (up to $15 million each) associated with the eXIthera and Veralox asset acquisitions.
- ATM Facility Usage: Monitor the remaining capacity and pricing trends of the ATM facility, which was a primary source of liquidity in Q1 2026.